バイオシミラー治療ペプチドの世界市場レポート 2025年

バイオシミラー治療ペプチド市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は16.1%で48億7,000万米ドルに成長します。予測期間の成長は、治療用途の拡大、世界の高齢化、市場競争、戦略的提携やパートナーシップ、非侵襲的治療に対する患者の嗜好などに起因しています。予測期間における主な動向としては、バイオテクノロジーの進歩、生物製剤の需要増加、製造における技術革新、コスト効率とヘルスケアへのアクセス重視、技術の進歩などが挙げられます。

高齢者はさまざまな慢性疾患にかかりやすくなるため、高齢化人口の増加が予測され、バイオシミラー治療ペプチド市場の成長を牽引するとみられます。世界保健機関（WHO）は、60歳以上の人口が2050年までに20億人に達すると推定しており、高齢者の慢性疾患の世界の増加は今後も続くとみられています。さらに、World Population Prospectsによれば、80歳以上の人口は2019年の1億4,300万人から2050年には4億2,600万人に急増すると予測されています。様々な慢性疾患やがんの治療に使用されるバイオシミラー治療ペプチドは、そのような健康状態に直面する高齢化人口の増加により、需要が増加する見込みです。

慢性疾患の蔓延も、バイオシミラー治療用ペプチド市場に拍車をかけると予想される要因の一つです。継続的な管理と治療を必要とする慢性疾患は世界的に増加傾向にあり、費用対効果の高い治療に対する需要が生じています。バイオシミラー治療ペプチドは手頃な価格の選択肢を提示し、患者のアクセスを向上させ、ヘルスケアシステムの持続可能性に貢献します。規制当局のサポートと臨床エビデンスが市場の成長をさらに後押しします。National Center for Biotechnology Informationによる予測では、50歳以上で少なくとも1つの慢性疾患を有する患者は、2020年の7,152万2,000人から2050年には1億4,266万人に達するという大幅な増加が見込まれています。その結果、慢性疾患の蔓延がバイオシミラー治療ペプチド市場の主要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオシミラー治療ペプチド PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバイオシミラー治療ペプチド市場：成長率分析
• 世界のバイオシミラー治療ペプチド市場の実績：規模と成長, 2019-2024
• 世界のバイオシミラー治療ペプチド市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオシミラー治療ペプチド総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオシミラー治療ペプチド市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 革新的
• ジェネリック
• 世界のバイオシミラー治療ペプチド市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口経路
• 経皮経路
• その他の投与経路
• 世界のバイオシミラー治療ペプチド市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 心血管系
• 中枢神経系
• 代謝障害
• 感染
• 血液疾患
• 胃腸障害
• 皮膚科
• 呼吸器疾患
• 世界のバイオシミラー治療ペプチド市場、革新的、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長時間作用型ペプチド
• 複合ペプチド
• 世界のバイオシミラー治療ペプチド市場、ジェネリックのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ホルモン
• 酵素

第7章 地域別・国別分析

• 世界のバイオシミラー治療ペプチド市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオシミラー治療ペプチド市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラー治療ペプチド市場：競合情勢
• バイオシミラー治療ペプチド市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceuticals Co. Ltd.
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• BioXpress Therapeutics SA
• Apotex Inc.
• Teva Pharmaceuticals Industries Ltd.
• Sandoz International GmbH
• Lonza Inc.
• Stada Arzneimittel AG
• Ipsen S.A
• Biocon Biopharmaceuticals Pvt. Ltd.
• Dr. Reddy's Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオシミラー治療ペプチド市場2029：新たな機会を提供する国
• バイオシミラー治療ペプチド市場2029：新たな機会を提供するセグメント
• バイオシミラー治療ペプチド市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biosimilar therapeutic peptides are peptide drugs utilized either in lieu of or in addition to peptide hormones when endogenous levels decrease. These biosimilar therapeutic peptides find applications in treating various conditions, including cancer, metabolic disorders, pulmonary diseases, cardiovascular ailments, and other illnesses.

The primary types of biosimilar therapeutic peptides are innovative and generic. It's common for biosimilar medications to be confused with generic drugs, as both are presented as cost-effective alternatives to high-priced name-brand medications. However, a key distinction lies in the fact that generics replicate synthetic pharmaceuticals, while biosimilars are derived from drugs containing biological organisms as active components. These therapeutic peptides are administered through different routes, including the parenteral route, transdermal route, and others, and are employed in the treatment of cancer, cardiovascular disorders, central nervous system conditions, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatological issues, and respiratory disorders.

The biosimilar therapeutic peptides market research report is one of a series of new reports from The Business Research Company that provides biosimilar therapeutic peptides market statistics, including global market size, regional shares, competitors with a biosimilar therapeutic peptides market share, detailed biosimilar therapeutic peptides market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilar therapeutic peptides industry. This biosimilar therapeutic peptide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar therapeutic peptides market size has grown exponentially in recent years. It will grow from $2.06 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 30.3%. The growth in the historic period can be attributed to increasing demand for cost-effective therapeutics, regulatory support and frameworks, patent expirations of biologic drugs, rising incidence of chronic diseases, and established manufacturing processes.

The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $4.87 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expanding therapeutic applications, the global aging population, market competitiveness, strategic collaborations and partnerships, and patient preference for non-invasive therapies. Major trends in the forecast period include advancements in biotechnology, increasing demand for biologics, technological innovations in manufacturing, focus on cost-efficiency and access to healthcare, and technological advancements.

The projected increase in the aging population is expected to drive the growth of the biosimilar therapeutic peptides market as the elderly are more susceptible to various chronic diseases. The global rise in chronic conditions among older individuals is set to continue, with the World Health Organization estimating that the population over 60 will reach 2 billion by 2050. Additionally, the number of people aged 80 and above is anticipated to surge from 143 million in 2019 to 426 million in 2050, as per World Population Prospects. Biosimilar therapeutic peptides, utilized in treating various chronic diseases and cancers, are poised to experience increased demand due to the growing aging population facing such health conditions.

The prevalence of chronic diseases is another factor expected to fuel the biosimilar therapeutic peptide market. Chronic diseases, necessitating ongoing management and treatment, are on the rise globally, creating a demand for cost-effective treatments. Biosimilar therapeutic peptides present an affordable option, enhancing patient access and contributing to the sustainability of healthcare systems. Regulatory support and clinical evidence further bolster market growth. Projections by the National Center for Biotechnology Information suggest a significant increase, reaching 142.66 million individuals aged 50 and older with at least one chronic illness by 2050, up from 71.522 million in 2020. Consequently, the prevalence of chronic diseases is a key driver for the biosimilar therapeutic peptides market.

Major companies in the biosimilar therapeutic peptide market are actively developing research platforms to optimize peptide synthesis, improve production efficiency, and ensure consistent quality throughout the drug discovery to commercialization process. Fujitsu Limited launched the Biodrug Design Accelerator platform in May 2023, aiming to expedite peptide drug discovery research and enhance efficiency in the design, make, test, analyze (DMTA) cycles. The platform supports scientists in pharmaceutical companies, facilitating accelerated and informed design of peptide drug candidates.

Major players in the biosimilar therapeutic peptide market are making substantial investments in developing biosimilar facilities to enhance production efficiency and ensure consistent quality throughout the entire process, from discovery to commercialization. An example of such strategic investment is seen in Sandoz Group AG, a Switzerland-based manufacturer of generic pharmaceuticals and biosimilars. By the year 2026, Sandoz plans to invest approximately $90 million in its facility located in Ljubljana, Slovenia. This investment aims to establish a dedicated Sandoz Biopharma Development Center, emphasizing the company's commitment to supporting the future growth of its biosimilar pipeline. Additionally, there are reports indicating the company's intentions to expand biosimilar development capabilities at its Holzkirchteen site in Germany, with a notable €25 million investment. This move is designed to consolidate Sandoz's advanced facilities and analytical expertise into one location.

In November 2022, Pfizer Inc., a prominent biopharmaceutical company based in the United States, made an announcement regarding the acquisition of Biohaven Pharmaceutical Holding Company Ltd. The financial details of the acquisition were undisclosed. Through this strategic move, Pfizer gains access to a portfolio featuring promising calcitonin gene-related peptide (CGRP) receptor antagonists, such as rimegepant and zavegepant. Additionally, Pfizer acquires a portfolio of pre-clinical CGRP assets from Biohaven Pharmaceutical Holding Company Ltd., a pharmaceutical company based in the U.S. known for offering late-stage product candidates targeting neurological illnesses. This acquisition further strengthens Pfizer's position in the biosimilar therapeutic peptide market.

Major companies operating in the biosimilar therapeutic peptides market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the biosimilar therapeutics market in 2024. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biosimilar therapeutic peptides market consists of sales of pegfilgrastim, bevacizumab, and adalimumab. Values in this market are """"factory gate values,"""" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Therapeutic Peptides Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar therapeutic peptides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar therapeutic peptides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar therapeutic peptides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Innovative; Generic
• 2) By Route Of Administration: Parenteral Route; Transdermal Route; Other Route Of Administrations
• 3) By Application: Cancer; Cardiovascular; Central Nervous Systems; Metabolic Disorders; Infection; Hematological Disorders; Gastrointestinal Disorders; Dermatology; Respiratory Disorders
• Subsegments:
• 1) By Innovative: Long-Acting Peptides; Combination Peptides
• 2) By Generic: Monoclonal Antibodies; Hormones; Enzymes
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilar Therapeutic Peptides Market Characteristics

3. Biosimilar Therapeutic Peptides Market Trends And Strategies

4. Biosimilar Therapeutic Peptides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biosimilar Therapeutic Peptides Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biosimilar Therapeutic Peptides PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biosimilar Therapeutic Peptides Market Growth Rate Analysis
• 5.4. Global Biosimilar Therapeutic Peptides Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biosimilar Therapeutic Peptides Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biosimilar Therapeutic Peptides Total Addressable Market (TAM)

6. Biosimilar Therapeutic Peptides Market Segmentation

• 6.1. Global Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Innovative
• Generic
• 6.2. Global Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral Route
• Transdermal Route
• Other Route Of Administrations
• 6.3. Global Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Cardiovascular
• Central Nervous Systems
• Metabolic Disorders
• Infection
• Hematological Disorders
• Gastrointestinal Disorders
• Dermatology
• Respiratory Disorders
• 6.4. Global Biosimilar Therapeutic Peptides Market, Sub-Segmentation Of Innovative, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Peptides
• Combination Peptides
• 6.5. Global Biosimilar Therapeutic Peptides Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Hormones
• Enzymes

7. Biosimilar Therapeutic Peptides Market Regional And Country Analysis

• 7.1. Global Biosimilar Therapeutic Peptides Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biosimilar Therapeutic Peptides Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimilar Therapeutic Peptides Market

• 8.1. Asia-Pacific Biosimilar Therapeutic Peptides Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimilar Therapeutic Peptides Market

• 9.1. China Biosimilar Therapeutic Peptides Market Overview
• 9.2. China Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimilar Therapeutic Peptides Market

• 10.1. India Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimilar Therapeutic Peptides Market

• 11.1. Japan Biosimilar Therapeutic Peptides Market Overview
• 11.2. Japan Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimilar Therapeutic Peptides Market

• 12.1. Australia Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimilar Therapeutic Peptides Market

• 13.1. Indonesia Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimilar Therapeutic Peptides Market

• 14.1. South Korea Biosimilar Therapeutic Peptides Market Overview
• 14.2. South Korea Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimilar Therapeutic Peptides Market

• 15.1. Western Europe Biosimilar Therapeutic Peptides Market Overview
• 15.2. Western Europe Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimilar Therapeutic Peptides Market

• 16.1. UK Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimilar Therapeutic Peptides Market

• 17.1. Germany Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimilar Therapeutic Peptides Market

• 18.1. France Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimilar Therapeutic Peptides Market

• 19.1. Italy Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimilar Therapeutic Peptides Market

• 20.1. Spain Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimilar Therapeutic Peptides Market

• 21.1. Eastern Europe Biosimilar Therapeutic Peptides Market Overview
• 21.2. Eastern Europe Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimilar Therapeutic Peptides Market

• 22.1. Russia Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimilar Therapeutic Peptides Market

• 23.1. North America Biosimilar Therapeutic Peptides Market Overview
• 23.2. North America Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimilar Therapeutic Peptides Market

• 24.1. USA Biosimilar Therapeutic Peptides Market Overview
• 24.2. USA Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimilar Therapeutic Peptides Market

• 25.1. Canada Biosimilar Therapeutic Peptides Market Overview
• 25.2. Canada Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimilar Therapeutic Peptides Market

• 26.1. South America Biosimilar Therapeutic Peptides Market Overview
• 26.2. South America Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimilar Therapeutic Peptides Market

• 27.1. Brazil Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimilar Therapeutic Peptides Market

• 28.1. Middle East Biosimilar Therapeutic Peptides Market Overview
• 28.2. Middle East Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimilar Therapeutic Peptides Market

• 29.1. Africa Biosimilar Therapeutic Peptides Market Overview
• 29.2. Africa Biosimilar Therapeutic Peptides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biosimilar Therapeutic Peptides Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biosimilar Therapeutic Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimilar Therapeutic Peptides Market Competitive Landscape And Company Profiles

• 30.1. Biosimilar Therapeutic Peptides Market Competitive Landscape
• 30.2. Biosimilar Therapeutic Peptides Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Biosimilar Therapeutic Peptides Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceuticals Co. Ltd.
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Novo Nordisk A/S
• 31.7. BioXpress Therapeutics SA
• 31.8. Apotex Inc.
• 31.9. Teva Pharmaceuticals Industries Ltd.
• 31.10. Sandoz International GmbH
• 31.11. Lonza Inc.
• 31.12. Stada Arzneimittel AG
• 31.13. Ipsen S.A
• 31.14. Biocon Biopharmaceuticals Pvt. Ltd.
• 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Biosimilar Therapeutic Peptides Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Therapeutic Peptides Market

34. Recent Developments In The Biosimilar Therapeutic Peptides Market

35. Biosimilar Therapeutic Peptides Market High Potential Countries, Segments and Strategies

• 35.1 Biosimilar Therapeutic Peptides Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biosimilar Therapeutic Peptides Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biosimilar Therapeutic Peptides Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer